

TRAINING UPDATE

Lab Location: Department:

FWMC, SGMC, WOMC Core Lab

Date Distributed: 2/7/25 Due Date: 2/21/25 Implementation: 2/14/25

DESCRIPTION OF PROCEDURE REVISION

Name of procedure:
Occult Blood AHC.U04
Description of change(s):
Implementing new QC: Sure-Vue Signature iFOBT Positive and Negative Control

Document your compliance with this training update by taking the quiz in the MTS system.

AHC.U04 Occult Blood

Copy of version 4.0 (in review)

Uncontrolled Copy printed on 2/7/2025 2:02 PM

Printed By

Demetra Collier (110199)

Organization

Adventist HealthCare

Approval and Periodic Review Signatures

Туре	Description	Date	Version	Performed By	Notes
Periodic review	Lab Service director	10/23/2023	3.0	Robert SanLuis Robert SanLuis	
Approval	Lab Director	10/29/2021	3.0	Nicolas Cacciabeve	
Approval	Core lab approvals	10/29/2021	3.0	Robert SanLuis Robert SanLuis	
Approval	QA approval	10/27/2021	3.0	Leslie Barrett	COKI
Approval	Lab Director	8/26/2020	2.0	Nicolas Cacciabeve	O PR
Approval	Core lab approvals	8/25/2020	2.0	Robert San Luis Robert San Luis	152:0L
Approval	QA approval	8/25/2020	2.0	Leslie Barrett	· Ca
Periodic review Captured outside MediaLab	Designated Reviewer	9/26/2018	1.0	Robert SanLuis	Recorded on 11/14/2018 by Leslie Barrett (104977) when document added to Document Control
Approval Captured outside MediaLab	Lab Director	10/6/2016	1.0	Nicolas Cacciabeve	Recorded on 11/14/2018 by Leslie Barrett (104977) when document added to Document Control

Approvals and periodic reviews that occurred before this document was added to Document Control may not be listed.

Prior History

Updated prefix 10/31/21

Version History

Version	Status	Туре	Date Added	Date Effective	Date Retired
3.0	Approved and Current	Major revision	10/27/2021	10/29/2021	Indefinite
2.0	Retired	Major revision	8/25/2020	8/26/2020	10/29/2021
1.0	Retired	First version in Document Control	11/14/2018	10/25/2016	8/26/2020

Linked Documents



Fort Washington Medical Center

Title: Occult Blood

Technical SOP

Title	Occult Blood		
Prepared by	Leslie Barrett and Daniel Adjei	Date:	7/28/2010
Owner	Robert SanLuis	Date:	10/3/2016

Laboratory Approval	Local Effective Date:	
Print Name and Title	Signature	Date
Refer to the electronic signature page for approval and approval dates.)e.	

TABLE OF CONTENTS

1.	Test Information	2
2.	Analytical Principle	2
3.	Specimen Requirements	2
4.	Reagents	3
5.	Calibrators/Standards	4
6.	Quality Control	4
7.	Quality Control Equipment And Supplies Procedure Calculations	6
8.	Procedure	6
9.	Calculations	7
10.	Reporting Results And Repeat Criteria	
11.	Expected Values	8
12.	Clinical Significance	9
13.	Procedure Notes	9
14.	Limitations Of Method	9
15.	Safety	10
16.	Related Documents	10
17.	References	10
18.	Revision History	10
19.	Addenda	11

SOP ID: AHC.U04 SOP Version # 4 CONFIDENTIAL: Authorized for internal use only

Fort Washington Medical Center

Title: Occult Blood

1. **TEST INFORMATION**

Assay	Method/Instrument	Test Code
Occult Blood	Oxidation of guaiac	OCBL

Synonyms/Abbreviations	
Guaiac Test	

Department	
Core Lab	^

2. ANALYTICAL PRINCIPLE

The Hemoccult® SENSA® test is a simplified and standardized variation of the guaiac procedure for the detection of occult blood. The Hemoccult® SENSA® test is based on the oxidation of guaiac by hydrogen peroxide to form a blue colored compound when hemoglobin is present in a stool specimen. Oxidation of alpha-guaiaconic acid (present in the guaiac paper) by hydrogen peroxide (present in the developer) is catalyzed by peroxidase (present in the heme portion of the hemoglobin) to form a highly conjugated blue quinone compound.

3. SPECIMEN REQUIREMENTS

3.1 **Patient Preparation**

rtion of the hemoglobin) to form a highly conjugated blue quinone compound.			
MEN REQUIREMENTS Patient Preparation	OF EFFECT		
Component	Special Notations		
Fasting/Special Diets	 For seven days before and during stool collection avoid non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen, or more than one adult aspirin a day. For three days before and during stool collection avoid vitamin C in excess of 250 mg a day and red meat. Eat a well-balanced diet including fiber such as bran cereals, fruit and vegetables. 		
Specimen Collection and/or Timing	 Three serial fecal specimens are recommended when screening asymptomatic patients. Avoid contact with toilet bowl waste. Do not collect specimens during a menstrual period, or while experiencing bleeding hemorrhoids or blood in the urine. 		
Special Collection Procedures	The stool specimens should be collected in a clean dry container, and then applied to the test card.		

SOP ID: AHC.U04 CONFIDENTIAL: Authorized for internal use only SOP Version #4 Page 2 of 11

Site: Shady Grove Medical Center, White Oak Medical Center,

Fort Washington Medical Center

Component	Special Notations
Other	N/A

Title: Occult Blood

3.2 Specimen Type & Handling

Criteria	
Type -Preferred	Stool
-Other Acceptable	An inoculated Hemocult Slide
Collection Container	Any clean dry container
Volume - Optimum	Small stool specimen
- Minimum	n/a
Transport Container and	Any clean dry container or Hemocult card at room
Temperature 🔥	temperature
Stability & Storage 🚫 🚬	Slides containing samples may be stored up to 14 days at
Requirements	room temperature before developing
· (Q	Refrigerated: Not acceptable
•	Frozen: Not acceptable
Timing Considerations	N/A
Unacceptable Specimens	Stool with visible blood. (This is usually due to
& Actions to Take	menstruation or active hemorrhoids)
	Request a recollection and credit the test with the
	appropriate LIS English text code for "test not performed"
	message. Examples: Wrong collection-UNAC. Document
	the request for recollection in the LIS.
Compromising Physical	None
Characteristics	°C _s .
Other Considerations	None

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Date of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation.

4. REAGENTS

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

4.1 Reagent Summary

Reagents / Kits	Supplier & Catalog Number
Hemoccult SENSA® Slide	Beckman Coulter, cat. # 64151
Hemoccult SENSA® Developer	Beckman Coulter, cat. # 64115

SOP ID: AHC.U04 CONFIDENTIAL: Authorized for internal use only SOP Version # 4 Page 3 of 11

Fort Washington Medical Center

4.2 **Reagent Preparation and Storage**

Assay Kit	
Reagent a	Hemoccult SENSA® Slide
Reagent b	Hemoccult SENSA® Developer
Container	N/A
Storage	Store at room temperature (15-30C). Protect from heat and light.
Stability	Stable until date printed on the vial
Preparation	None

Title: Occult Blood

Note: Do not interchange Hemoccult® SENSA® with Hemoccult test reagents (yellow/green striped bottle) or with reagents from another manufacturer.

CALIBRATORS/STANDARDS **5.**

Not applicable

6. QUALITY CONTROL

6.1 **Controls Used**

6.1.1 Internal Control

olicable	
ITY CONTROL	A .
Controls Used	Vox.
6.1.1 Internal Control	1
Controls	Supplier and Catalog Number
Internal Positive Control	Included in each Hemoccult® SENSA® card (see 4.1)
Internal Negative Control	6

6.1.2 External Control

Controls	Supplier and Catalog Number
Sure-Vue Signature iFOBT Positive Control	Fisher Scientific Cat. no. 25164
Sure-Vue Signature iFOBT Negative Control	Fisher Scientific Cat. no. 25165

6.2 Control Preparation and Storage

Control	Internal Procedural Controls
Contents	Positive performance monitor area on Hemoccult® SENSA® card: a hemoglobin derived catalyst impregnated into the test card. Negative performance monitor area on Hemoccult® SENSA® card: no catalyst.
Preparation	None
Storage/Stability	Store at 15-30C until manufacturer's expiration date

SOP ID: AHC.U04 CONFIDENTIAL: Authorized for internal use only Page 4 of 11 SOP Version #4

Site: Shady Grove Medical Center, White Oak Medical Center,

Fort Washington Medical Center

Control	External Control	
Contents	Sure-Vue Signature iFOBT Positive and Negative Control	
Preparation	None	
Storage/Stability	Store at 2 – 8° C	
	Keep capped when not in use.	
	Stable until manufacturer's expiration date	

Title: Occult Blood

6.3 Frequency

- Internal procedural controls are performed with each test.
- The external positive and negative controls are performed once per week and whenever a new lot of Hemoccult SENSA® Slides is introduced.

6.4 Tolerance Limits and Criteria for Acceptable QC

6.4.1 Internal Controls

The Performance Monitor **positive** area of the Hemoccult Card will turn **blue** when the developer has been added within 10 seconds and will stay stable for 60 seconds. The Performance Monitor **negative** area will not turn a color.

Note: Always develop the test, read the results, interpret them and make a decision as to whether the fecal specimen is positive or negative for occult blood **BEFORE** developing the Performance Monitors. Do not apply Developer to Performance Monitors before interpreting test results. Any blue originating from the Performance Monitors should be ignored in the reading of the specimen test results.

6.4.2 External Controls

The positive control will turn blue when the developer has been added within 30 seconds.

The negative control will not turn a color.

SOP ID: AHC.U04 CONFIDENTIAL: Authorized for internal use only SOP Version # 4 Page 5 of 11

Fort Washington Medical Center

Title: Occult Blood

6.4.3 Corrective Action for Failed Controls

IF	THEN	
Any control does not produce the expected result	The test is invalid. Do not report patient results. Repeat testing using a new card.	
	Do not report patient results until acceptable QC results are obtained.	
	If repeat testing does not produce acceptable QC, then notify supervisor immediately.	

6.5 **Documentation**

The results of the controls are documented on the appropriate manual QC log sheet.

6.6 **Quality Assurance Program**

- For each new lot number of reagent the internal and external control must be tested. Performance of the new lot must be equivalent to the previous lot.
- Training must be successfully completed and documented prior to performing this test. This procedure will be incorporated into the departmental competency assessment program.
- The laboratory participates in CAP proficiency testing.
- All technologists are tested for color blindness as part of the pre-employment a. Siffective testing.

7. **EQUIPMENT and SUPPLIES**

7.1 **Assay Platform**

Not applicable

7.2 **Equipment**

Not applicable

7.3 **Supplies**

Applicator sticks

8. **PROCEDURE**

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

SOP ID: AHC.U04 CONFIDENTIAL: Authorized for internal use only Page 6 of 11 SOP Version #4

Site: Shady Grove Medical Center, White Oak Medical Center,

Fort Washington Medical Center

If the specimen is a raw stool follow these directions: 8.1 1. Collect a small stool sample on the end of an applicator stick. Open the front tab of the Hemoccult Slide. 3. Apply thin smear covering Box A. Obtain a second sample from a different part of stool. Apply thin smear covering Box 4. В. Close cover flap. 5. Slides are best developed no sooner than three (3) days after the sample application to 6. allow for degradation of any fruit and vegetable peroxidases that may be in the fecal sample. However, if immediate testing is required, wait 3 to 5 minutes before developing. Open the flap in back of slide and apply 2 drops of Hemoccult Developer to guaiac 7. paper directly over each smear. 8. Read results within 60 seconds ANY TRACE OF BLUE ON OR AT THE EDGE OF THE SMEAR IS POSITIVE 9. FOR OCCULT BLOOD.

Title: Occult Blood

8.2	If the specimen is submitted on the Hemoccult Slide:
1.	Begin with 8.1 step 6 and proceed to 8.1 step 8.

8.3	External Control Testing
1.	Positive Control : Gently mix the Fecal Occult Blood Camco Positive Control by several inversions. Place one drop on the 'control' area on the back of the Hemoccult SENSA Slide.
2.	After the drop has been absorbed, add two (2) drops of Developer to the 'control' area.
3.	A blue color should form within thirty (30) seconds. Read result up to thirty seconds Disregard any colors that form after thirty seconds
	If no color forms, the test is invalid and the patient results must not be reported . Refer to section 6.4 for corrective action.
	Note : The blue color from the positive control should not be regarded as the intensity required from a positive patient test for occult blood in the stool.
4.	Negative Control : Place one or two drops of deionized water on the 'control' area on the back of the Hemoccult SENSA Slide.
5.	After the water has been absorbed, add two (2) drops of Developer to the 'control' area
6.	No color should form within thirty (30) seconds. If any color forms, the test is invalid and the patient results must not be reported . Refer to section 6.4 for corrective action.

9. **CALCULATIONS**

Not applicable

SOP ID: AHC.U04 CONFIDENTIAL: Authorized for internal use only Page 7 of 11 SOP Version #4

Fort Washington Medical Center

Title: Occult Blood

10. REPORTING RESULTS AND REPEAT CRITERIA

10.1 Interpretation of Data

Negative results: No detectable blue on or at the edge of the smears indicates test is negative for occult blood.

Positive results: Any trace of blue on or at the edge of one or more of the smears indicates test is positive for occult blood.

10.2 Rounding

Not applicable

10.3 Units of Measure

Not applicable

10.4 Clinically Reportable Range (CRR)

Not applicable

10.5 Review Patient Data

- Review patient results for unusual patterns, trends or distribution.
- Report atypical or unexpected results or trends for this test to appropriate supervisory personnel, prior to releasing results.

10.6 Repeat Criteria and Resulting

IF the result is	THEN	
Negative	Report as NEG in the LIS	
Positive	Report as POS in the LIS	

11. EXPECTED VALUES

11.1 Reference Ranges

Negative

11.2 Critical Values

None established

11.3 Standard Required Messages

None established

SOP ID: AHC.U04 CONFIDENTIAL: Authorized for internal use only SOP Version # 4 Page 8 of 11

Fort Washington Medical Center

12. CLINICAL SIGNIFICANCE

This is a test for detecting fecal occult blood which may be indicative of gastrointestinal diseases. It is not a test for colorectal cancer or any other specific diseases.

Title: Occult Blood

13. PROCEDURE NOTES

FDA Status: Approved/cleared

Validated Test Modifications: None

14. LIMITATIONS OF METHOD

Petiteo 14.1 **Analytical Measurement Range (AMR)**

N/A

14.2 **Precision**

- Bowel lesions, including some polyps and colorectal cancers, may not bleed at all or may bleed intermittently. Also, blood, if present, may not be distributed uniformly in the fecal specimen. Consequently, a test result may be negative even when disease is present.
- Conversely, a Hemoccult SENSA test result may be positive on specimens from healthy patients. This may be due to interfering substances in the diet or to medications. It may also be due to low but detectable levels of blood loss, common to both healthy adults and patients with gastrointestinal disease.
- Results with the Hemoccult SEMSA test cannot be considered conclusive evidence of the presence or absence of gastrointestinal bleeding or pathology. Hemoccult SENSA tests are designed for preliminary screening as an aid to diagnosis. They are not intended to replace other diagnostic procedures such as sigmoidoscopy, colonoscopy, barium enema, or other x-ray studies.
- The Hemoccult SENSA test, as well as other unmodified fecal occult blood tests, should not be used to test gastric specimens. Interfering factors, such as low pH, high drug concentrations, metal ions or plant peroxidase in food may affect the function of guiac-based occult blood tests. Gastroccult, available from Beckman Coulter Primary Care Diagnostics, is specifically designed to detect occult blood in gastric specimens.
- Addition of a drop of water (rehydration) to the guiac test card prior to the addition of the developer increases the sensitivity of the test, but also increases the number of false-positive test results. For this reason, Rehydration in not a recommended procedure for the Hemoccult SENSA test.

CONFIDENTIAL: Authorized for internal use only SOP ID: AHC.U04 Page 9 of 11 SOP Version #4

Fort Washington Medical Center

Title: Occult Blood

14.3 Interfering Substances

Substances which can cause false-positive test results:

- Corticosteroids, phenylbutazone, reserpine, anticoagulants, antimetabolites, and cancer chemotherapeutic drugs
- Alcohol in excess
- The application of antiseptic preparations containing iodine (providone/iodine mixture)

14.4 Clinical Sensitivity/Specificity/Predictive Values

Not available

15. SAFETY

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

16. RELATED DOCUMENTS

Current package insert for Hemoccult SENSA® Occult Blood Quality Control Log (AG.F31)

17. REFERENCES

- 1. Package insert, Hemoccult SENSA®, Beckman Coulter, Inc., June 2015
- 2. Package insert, Fecal Occult Blood Camco Positive Control Solution, Cambridge Diagnostics Products, 3/10.

18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval
			Supersedes SOP U002.001		
000	10/3/16		Update owner	L Barrett	R SanLuis
000	10/3/16	Header	Add WAH	L Barrett	R SanLuis
000	10/3/16	4,6	Remove individual section labeling instructions and add general one	L Barrett	R SanLuis
000	10/3/16	10.5	Review data moved from section 6	L Barrett	R SanLuis
000	10/3/16	15	Update to new standard wording	L Barrett	R SanLuis
000	10/3/16	16	Form moved from section 19	L Barrett	R SanLuis
000	10/3/16	17	Update PI revision date	L Barrett	R SanLuis
000	10/3/16	Footer	Version # leading zero's dropped due to new EDCS in use as of 10/7/13	L Barrett	R SanLuis

SOP ID: AHC.U04 CONFIDENTIAL: Authorized for internal use only SOP Version # 4 Page 10 of 11

Site: Shady Grove Medical Center, White Oak Medical Center,

Fort Washington Medical Center

Version	Date	Section	Reason	Reviser	Approval
1	8/25/20	Header	Changed WAH to WOMC	L Barrett	R SanLuis
2	10/27/21	Header	Added FWMC	L Barrett	R SanLuis
2	10/27/21	Footer	Updated prefix to AHC	L Barrett	R SanLuis
3	02/04/25	6.1 & 6.2	Updated to new external control material	A Chini	R SanLuis

Title: Occult Blood

19. ADDENDA

None



CONFIDENTIAL: Authorized for internal use only SOP ID: AHC.U04 Page 11 of 11 SOP Version #4